XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
EARNINGS PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Year Ended December 31,
202320222021
Warrants——457,753
Stock option awards1,214,560629,690490,968
Restricted stock awards340,331205,652316,454
Performance stock unit awards———
Schedule of Basic and Diluted Earnings Per Share
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202320222021
Numerator:  
Net income (1) (2) (3)$267,090 $150,556 $139,898 
Denominator:  
Weighted average number of common shares outstanding178,973 181,105 179,855 
Earnings per Common Share:
Earnings per common share, basic$1.49 $0.83 $0.78 
(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions and Divestitures, for further discussion. In addition, net income includes approximately $5.3 million of other non-operating income.
(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, Business Acquisitions and Divestitures, for further discussion.
(3) Net income for the year ended December 31, 2021 includes the impact of the Company’s release of its valuation allowance.
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202320222021
Numerator:  
Net income (1) (2) (3)$267,090 $150,556 $139,898 
Denominator:  
Weighted average number of common shares outstanding178,973 181,105 179,855 
Effect of dilutive securities1,402 970 1,350 
Weighted average number of common shares outstanding, diluted180,375 182,075 181,205 
Earnings per Common Share:
Earnings per common share, diluted$1.48 $0.83 $0.77 
(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions and Divestitures, for further discussion. In addition, net income includes approximately $5.3 million of other non-operating income.
(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, Business Acquisitions and Divestitures, for further discussion.
(3) Net income for the year ended December 31, 2021 includes the impact of the Company’s release of its valuation allowance.